Rebates Resources
Talking Points
- DIR and Stars Talking Points
- Don’t Disrupt Drug Coverage for 48 Million Americans on Hope Alone
- Explaining Types of Pharmacy Benefit Contracts
- Finalizing the Rebate Rule Increases Premiums and Government Costs
- HHS Final Rebate Rule Hurts Medicare Beneficiaries and Rewards Drugmakers
- Importance of Retaining Pharmacy DIR During the COVID-19 Pandemic
- Pitfalls of Point-of-Sale Drug Rebates and Pharmacy Price Concessions in Part D
- Putting into Appropriate Context the Growth of Pharmacy DIR
- Risk Mitigation and Pass-through Contracting for Pharmacy Benefit Services
- Setting the Record Straight - PBM Pricing Practices in Florida SMMC Program
- With Point-of-Sale Rebates, Everyone Pays Except Manufacturers - Milliman (2021)
- With Point-of-Sale Rebates, Everyone Pays Except Manufacturers (2021)
Infographics
- Infographic, Findings of OIG and GAO Reports on Rebates (2019)
- Infographic, How Medicare Part D DIR Works (2019)
- Infographic, How Performance-based Contracts Work for Pharmacies
- Infographic, How Spread Pricing Helps Drive Lower Drug Costs (2020)
- Infographic, New Data Shows Price Increases Unrelated to PBM Negotiated Rebates (2020)
- Infographic, Premium Impact of Disallowing Rebates (2018)
- Infographic, Public Sector Healthcare Roundtable Survey (2020)
- Infographic, Rebuttal of USC Schaeffer's The Association Between Drug Rebates and List Prices (2020)
ALL CONTENT ON THIS PAGE IS CONFIDENTIAL, for INTERNAL PCMA USE ONLY
